Advances in Laser Scanning Imaging Cytometry for High-Content Screening

Assay and Drug Development Technologies

Volumn 13, Issue 2, 2015, Pages 66-78

  Wylie, Paul G ^a   Onley, David J ^a   Hammerstein, Anne F ^a   Bowen, Wayne P ^a  

^a TTP Labtech Limited Melbourn Science Park   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL CYCLE; CELL INVASION; CELL MIGRATION; CYTOMETRY; HIGH CONTENT SCREENING; HUMAN; IMAGE ANALYSIS; LASER SCANNING IMAGING CYTOMETRY; PRODUCT DEVELOPMENT; REVIEW; RNA INTERFERENCE; SCREENING; WORKFLOW; ANIMAL; BIOASSAY; CONFOCAL MICROSCOPY; DEVICES; DRUG SCREENING; EQUIPMENT DESIGN; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; TRENDS;

ANIMALS; BIOLOGICAL ASSAY; DRUG EVALUATION, PRECLINICAL; EQUIPMENT DESIGN; FLOW CYTOMETRY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSCOPY, CONFOCAL;

EID: 84924980323     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2014.607     Document Type: Review

References (88)

1. Giuliano KA, Haskins JR, Taylor DL: Advances in high content screening for drug discovery. Assay Drug Dev Technol 2003;1:565-577.
2. Bowen WP, Wylie PG: Application of laser-scanning fluorescence microplate cytometry in high content screening. Assay Drug Dev Technol 2006;4:209-221.
3. Horman SR, To J, Orth AP: An HTS-compatible 3D colony formation assay to identify tumor-specific chemotherapeutics. J Biomol Screen 2013;18:1298-1308.
4. Lu X, Boora U, Seabra L, et al.: Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN). Oncogene 2013;33:956-965.
5. Luo Q, Tang L, Lin H, et al.: The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer. Lung Cancer 2013;84:190-195.
6. Ming W, Ma W, Chen LH, et al.: Development and validation of a 96-well cellular assay for the discovery of ALDH1A1 inhibitors. Assay Drug Dev Technol 2013;11:388-395.
7. Posthumadeboer J, Piersma SR, Pham TV, et al.: Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer 2013;109:2142-2154.
8. Roguev A, Talbot D, Negri GL, et al.: Quantitative genetic-interaction mapping in mammalian cells. Nat Methods 2013;10:432-437.
9. Sherman SP, Pyle AD: Small molecule screening with laser cytometry can be used to identify pro-survival molecules in human embryonic stem cells. PLoS One 2013;8:e54948.
10. Smith EB, Ogert RA, Pechter D: HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4. J Biomol Screen 2014;19:108-118.
11. Torres-Guzmán R, Chu S, Velasco JA, Lallena MJ: Multiparametric cell-based assay for the evaluation of transcription inhibition by high-content imaging. J Biomol Screen 2013;18:556-566.
12. Davies BR, Greenwood H, Dudley P, et al.: Preclinical pharmacology of AZD5363, an orally bioavailable inhibitor of AKT: pharmacodynamics, antitumor activity and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012;11:873-887.
13. Gavine PR, Mooney L, Kilgour E, et al.: AZD4547: an orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012;72:2045-2056.
14. Gerlinger M, Santos CR, Spencer-Dene B, et al.: Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol 2012;227:146-156.
15. Heald RA, Jackson P, Savy P, et al.: Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions. J Med Chem 2012;55:4594-4604.
16. Lee CY, Johnson RL, Wichterman-Kouznetsova J, et al.: High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them. Methods 2012;57:234-248.
17. Liu QH, Zhang J, Zhao CY, et al.: Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. Cancer Lett 2012;314:119-125.
18. Kim KJ, Wang J, Xu X, et al.: A chemical genomics screen to discover genes that modulate neural stem cell differentiation. J Biomol Screen 2012;17:129-139.
19. Sato S, Drake AW, Tsuji I, Fan J: A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF. PLoS One 2012;7:e51964.
20. Titus SA, Southall N, Marugan J, Austin CP, Zheng W: High-throughput multiplexed quantitation of protein aggregation and cytotoxicity in a Huntington's disease model. Curr Chem Genomics 2012;6:79-86.
21. Fursov N, Gates IV, Panavas T, Giles-Komar J, Powers G:. Development and utilization of activated STAT3 detection assays for screening a library of secreted proteins. Assay Drug Devel Technol 2011;9:420-429.
22. Horn T, Sandmann T, Fischer B, Axelsson E, Huber W, Boutros M: Mapping of signaling networks through synthetic genetic interaction analysis by RNAi. Nat Methods 2011;8:341-346.
23. Kveiborg M, Instrell R, Rowlands C, Howell M, Parker PJ: PKCα and PKCδ regulate ADAM17-mediated ectodomain shedding of heparin binding-EGF through separate pathways. PLoS One 2011;6:e17168.
24. Lu X, Wei W, Fenton J, et al.: Therapeutic targeting the loss of the birt-hoggdube suppressor gene. Mol Cancer Ther 2011;10:80-89.
25. Zhao G, Li WY, Chen D, et al.: A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad-spectrum of anti-tumor activity in several tumor xenograft models. Mol Cancer Ther 2011;10:2200-2210.
26. Zhu W, Lee CY, Johnson RL, Wichterman J, Huang R, DePamphilis ML: An image based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cells. Mol Cancer Res 2011;9:294-310.
27. Chresta CM, Davies BR, Hickson I, et al.: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-298.
28. Gupta S, Iljin K, Sara H, Mpindi JP, et al.: FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010;70:6735-6745.
29. Hickinson DM, Klinowska T, Speake G, et al.: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 2010;16:1159-1169.
30. Phong MS, Van Horn RD, Li S, Tucker-Kellogg G, Surana U, Ye XS: The p38 MAPK promotes cell survival in response to DNA damage but is not required for G2 DNA damage checkpoint in human cancer cells. Mol Cell Biol 2010;30:3816-3826.
31. Nevo J, Mai A, Tuomi S, et al.: Mammary-derived growth inhibitor (MGDI) interacts with integrin alpha-subunits and supresses integrin activity and invasion. Oncogene 2010;29:6452-6463.
32. Wang YJ, McKenna PM, Hrin R, et al.: Assessment of the susceptibility of mutant HIV-1 to antiviral agents. J Virol Methods 2010;165:230-237.
33. Dessole G, Branca D, Ferrigno F, et al.: Discovery of N-[(1-aryl-1H-indazol-5-yl)methyl]amides derivatives as smoothened antagonists for inhibition of the hedgehog pathway. Bioorg Med Chem Lett 2009;19:4191-4415.
34. Forte E, Luftig MA: MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J Virol 2009;83:2491-2499.
35. Klinghoffer RA, Frazier J, Annis J, et al.: A lentivirus-mediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of beta-catenin/GSK3 signaling. PLoS One 2009;4:e6892.
36. Maloney SL, Sullivan DC, Suchting S: Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane. Br J Cancer 2009;101:957-966.
37. Nevo J, Mattila E, Pellinen T, et al.: Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. Clin Cancer Res 2009;15:6570-6581.
38. Salmela AL, Pouwels J, Varis A, et al.: Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. Carcinogenesis 2009;30:1032-1040.
39. Baus D, Heermeier K, De Hoop M, et al.: Identification of a novel AS160 splice variant that regulates GLUT4 translocation and glucose-uptake in rat muscle cells. Cell Signal 2008;20:2237-2246.
40. Johnson RL, Huanga W, Jadhava A, Austin CP, Inglese J, Martinez ED: A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression. Anal Biochem 2008;375:237-248.
41. Beller M, Sztalryd C, Southall N, et al.: COPI complex is a regulator of lipid homeostasis. PLoS Biol 2008;6:e292.
42. Lehto M, Mäyränpää MI, Pellinen T, et al.: The R-Ras interaction partner ORP3 regulates cell adhesion. J Cell Sci 2008;121:695-705.
43. Schmidt RJ, Zhang Y, Zhao Y, et al.: A novel splicing variant of proprotein convertase subtilisin/kexin type 9. DNA Cell Biol 2008;27:183-189.
44. Vuoriluoto K, Jokinen J, Kallio K, Salmivirta M, Heino J, Ivaska J: Syndecan-1 supports integrin a2b1-mediated adhesion to collagen. Exp Cell Res 2008;314:3369-3381.
45. Qian YW, Schmidt RJ, Zhang Y, et al.: Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007;48:1488-1498.
46. Auld DS, Johnson RL, Zhang YQ, et al.: Fluorescent protein-based cellular assays analysed by laser scanning cytometry in 1536-well format. Methods Enzymol 2006;414:566-589.
47. Pellinen T, Arjonen A, Vuoriluoto K, Kallio K, Fransen JA, Ivaska J: Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of beta1-integrins. J Cell Biol 2006;173:767-780.
48. Swinney DC: The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J Biomol Screen 2013;18:1186-1192.
49. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ: Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Chem 2012;55:4527-4538.
50. Acumen Cellista Microplate Cytometer: http://ttplabtech.com/cell-imaging/Acumen (Last accessed on November 3, 2014).
51. ImageJ: Image Processing and Analysis in Java: http://imagej.nih.gov/ij/ (Last accessed on November 3, 2014).
52. CellProfiler: Cell Image Analysis Software: www.cellprofiler.org/ (Last accessed on November 3, 2014).
53. O'Brien PJ, Irwin W, Diaz D, et al.: High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 2006;80:580-604.
54. Kittler R, Pelletier R, Heninger A-K, et al.: Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 2007;9:1401-1412.
55. Swanton C, Nicke B, Schuett M, et al.: Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A 2009;106:8671-8676.
56. Karlas A, Machuy N, Shin Y, et al.: Genome-wide RNAi screen identified human host factors crucial for influenza virus replication. Nature 2010;463:818-822.
57. Fuchs F, Pau G, Kranz D, et al.: Clustering phenotype populations by genome-wide RNAi and multiparametric imaging. Mol Syst Biol 2010;6:370.
58. Kam Y, Guess C, Estrada L, Weidow B, Quaranta V: A novel circular invasion assay mimics in vivo invasive behavior of cancer cell lines and distinguishes single-cell motility in vitro. BMC Cancer 2008;8:198-209.
59. Oris™ Cell Migration Assays. www.platypustech.com/cellassays.html (Last accessed on November 3, 2014).
60. Gough W, Hulkower KI, Lynch R, McGlynn P, Uhlik M, Yan L, Lee JA: A quantitative, facile, and high-throughput image-based cell migration method is a robust alternative to the scratch assay. J. Biomol Screen 2011;16:155-163.
61. Alemany-Ribes M, Semino CE: Bioengineering 3D environments for cancer models. Adv Drug Deliv Rev 2014;79-80C:40-49.
62. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA: Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010;148:3-15.
63. Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development Annu Rev Pathol 2006;1:119-150.
64. Lu P, Weaver VM, Werb Z: The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196:395-406.
65. Pampaloni F, Reynaud EG, Stelzer EH: The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007;10:839-845.
66. Collins MA: Generating 'Omic Knowledge': the role of informatics in high content screening. Comb Chem High Throughput Screen 2009;12:917-925.
67. Isherwood BJ, Walls RE, Roberts ME, Houslay TM, Brave SR, Barry ST, Carragher NO: High-content analysis to leverage a robust phenotypic profiling approach to vascular modulation. J Biomol Screen 2013;10:1246-1259.
68. Michael S, Inglese J, Shukla S, Hasson S, Titus S, Auld DS, Guha J: Connecting high throughput to high content in screening: the Wells to Cells workflow. www.wakoautomation.com/media/documents/ConnectingHT2HCPoster.pdf (Last accessed on November 3, 2014).
69. Shukla S, Huang R, Austin C.P, Menghang X: The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov Today 2010;15:997-1007.
70. Chawla K, Masuda K, Sah RL: Tracking chondrocytes and assessing their proliferation with carboxyfluorescein diacetate succinimidyl ester: effects on cell functions. Tissue Eng Part C Methods 2010;6:301-310.
71. Chan GKY, Kleinheinz TL, Peterson D, Moffat JG: A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS One 2013;8:e63583.
72. Gartner ZJ, Bertozzi CR: Programmed assembly of 3-dimensional microtissues with defined cellular connectivity. Proc Natl Acad Sci U S A 2009;106:4606-4610.
73. Wylie PG, Bowen WP: Determination of cell colony formation in a high-content screening assay. Clin Lab Med 2007;27:193-199.
74. Wylie PG, Janes M: High-content cytotoxicity analysis. GEN 2009;29:11.
75. Caretti V, Hiddingh L, Lagerweij T, et al.: WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol Cancer Ther 2013;12:141-150.
76. Carver J, Dexheimer TS, Hsu D, et al.: A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. PLoS One 2014;9:e103836.
77. Martin HL, Adams M, Higgins J: High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markers. PLoS One 2014;9:e88338.
78. Blackmore MG, Moore DL, Smith RP, et al.: High content screening of cortical neurons identifies novel regulators of axon growth. Mol Cell Neurosci 2010;44:43-54.
79. Vybrant® DyeCycle™ Green and Orange Stains: http://tools.lifetechnologies.com/content/sfs/manuals/mp35004.pdf (Last accessed on November 3, 2014).
80. Smith PJ, Wiltshire M, Davies S, Patterson LH, Hoy T: A novel cell permeant and far red-fluorescing DNA probe, DRAQ5, for blood cell discrimination by flow cytometry. J Immunol Methods 1999;229:131-139.
81. Simonen M, Ibig-Rehm Y, Hofmann G, et al.: High-content assay to study protein prenylation. J Biomol Screen 2008;13:456-467.
82. Lipophilic Tracers-Dil, DiO, DiD, DiA, and DiR: http://tools.lifetechnologies.com/content/sfs/manuals/mp00282.pdf (Last accessed on November 3, 2014).
83. Qtracker® Cell Labeling Kits: http://tools.lifetechnologies.com/content/sfs/manuals/mp10198.pdf (Last accessed on November 3, 2014).
84. Alexa Fluor Dyes: www.mobitec.de/probes/docs/sections/0103.pdf (Last accessed on November 3, 2014).
85. Srour EF, Leemhuis T, Brandt JE, vanBesien K, Hoffman R: Simultaneous use of rhodamine 123, phycoerythrin, Texas red, and allophycocyanin for the isolation of human hematopoietic progenitor cells. Cytometry 1991;12:179-183.
86. Comley J: High content screening-emerging importance of novel reagents/probes and pathway analysis. Drug Discov World 2005;6:31-53.
87. Nyfeler B, Bergman P, Triantafellow E, et al.: Relieving Autophagy and 4EBP1 from Rapamycin Resistance. Mol Cell Biol 2011;31:2867-2876.
88. LiveBLAzer™ FRET-B/G Loading Kit: http://tools.lifetechnologies.com/content/sfs/manuals/liveblazer-FRETBGLoadingKit-man.pdf (Last accessed on November 3, 2014).